Varinder Kaur

Employment

• University of Virginia Associate Professor
  2016 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (51)

• Table S10 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705263
  +Save
• Data from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.c.8542108
  +Save
• Complete Response to Nivolumab‐Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First‐Line Nivolumab‐Ipilimumab: A Case Report
  Cancer Reports 2026 DOI: 10.1002/cnr2.70544
  +Save
• Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  Cancer Research Communications 2026 DOI: 10.1158/2767-9764.CRC-25-0744
  +Save
• Table S9 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705230
  +Save
• Table S8 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705233
  +Save
• Table S7 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705236
  +Save
• Table S6 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705239
  +Save
• Table S5 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705242
  +Save
• Table S4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
  2026 DOI: 10.1158/2767-9764.32705245
  +Save